David Routman, MD, Mayo Clinic, Rochester, MN, discusses the latest research investigating the use of circulating tumor human papillomavirus DNA (ctHPVDNA) to detect cancer recurrence. It was found that patients with detectable ctHPVDNA were at higher risk of recurrence and reduced progression-free survival (PFS) compared to patients without ctHPVDNA, supported by data showing that the difference in PFS between these patients was 20%. Future research will investigate whether patients with detectable ctHPVDNA will have better outcomes after de-escalated adjuvant radiation therapy (DART) compared to patients without ctHPVDNA, enabling optimal selection of patients that will benefit from this therapy. This interview took place at the American Society for Radiation Oncology (ASTRO) 2022 Congress in San Antonio, Tx.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.